Cardiovascular risk factors and mortality in patients with coronary heart disease

被引:0
作者
Christof Prugger
Jürgen Wellmann
Jan Heidrich
Stefan-Martin Brand-Herrmann
Ulrich Keil
机构
[1] University of Münster,Institute of Epidemiology and Social Medicine
[2] University of Münster,Leibniz
来源
European Journal of Epidemiology | 2008年 / 23卷
关键词
Coronary heart disease; Germany; Mortality; Secondary prevention;
D O I
暂无
中图分类号
学科分类号
摘要
A priority in preventive cardiology is to reduce the number of recurrent events and to prolong survival in patients with established coronary heart disease (CHD). Aim of the present study was to examine risk factors for long-term mortality in CHD patients who entered routine secondary prevention after a coronary event or intervention. Such patients, from the EUROASPIRE (EUROpean Action on Secondary Prevention through Intervention to Reduce Events) I and II studies in the region of Münster, Germany, were followed over a mean period of 8.0 years up to the end of 2005. Patients were up to 70 years of age at baseline when they were interviewed and examined using standardised methods. Baseline examination was carried out at least 6 months and at a mean of 19.5 months after the coronary event or procedure. In 367 patients from EUROASPIRE I and 380 patients from EUROASPIRE II, a total of 125 deaths (16.7%) occurred during follow-up. Multivariate analyses, using Cox proportional hazards models, established diabetes mellitus and smoking as predictors for all-cause mortality with estimated hazard rate ratios (HRRs) of 2.24 (95% confidence interval (CI): 1.43–3.49) and 1.95 (95% CI: 1.23–3.10), respectively. Significant associations were found between diabetes mellitus and cardiovascular (HRR 2.36; 95% CI: 1.31–4.24) as well as CHD mortality (HRR 2.40; 95% CI: 1.25–4.59). Systolic blood pressure was significantly associated with increased cerebrovascular disease mortality (HRR 1.04; 95% CI: 1.01 and 1.08 for 1 mmHg increase). In conclusion, long-term mortality in coronary patients from routine secondary prevention is substantial. Diabetes mellitus and smoking represent key issues in patients with established CHD.
引用
收藏
页码:731 / 737
页数:6
相关论文
共 48 条
[1]  
Lopez AD(1998)The global burden of disease, 1990–2020 Nat Med 4 1241-3
[2]  
Murray CC(2007)Fourth Joint European Societies’ Task Force on Cardiovascular Disease Prevention in Clinical Practice Eur J Cardiovasc Prev Rehabil 14 S1-113
[3]  
Chambless L(1997)Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985–1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease Circulation 96 3849-59
[4]  
Keil U(2001)Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators J Am Coll Cardiol 38 56-63
[5]  
Dobson A(2001)Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment Eur Heart J 22 1119-27
[6]  
Marschner IC(1997)European action on secondary prevention through intervention to reduce events. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results Eur Heart J 18 1569-82
[7]  
Colquhoun D(2001)Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme Eur Heart J 22 554-95
[8]  
Simes RJ(2003)Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort Eur J Cardiovasc Prev Rehabil 10 289-7
[9]  
Wilhelmsen L(2007)Primary risk factors influence risk of recurrent myocardial infarction/death from coronary heart disease: results from the Stockholm Heart Epidemiology Program (SHEEP) Eur J Cardiovasc Prev Rehabil 14 532-52
[10]  
Pyorala K(2007)Outcome after coronary artery bypass graft surgery, coronary angioplasty and stenting Int J Cardiol 116 46-64